ArticleInternational journal of pharmaceutics: X2026
Palonosetron-loaded binary ethosome-incorporated transdermal gel: Formulation optimization, in vitro/in vivo evaluation, and therapeutic efficacy in chemotherapy-induced nausea and vomiting.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop a transdermal gel formulation of palonosetron-loaded binary ethosomes (PAL-BE-G) and systematically evaluate its in vitro physicochemical properties, in vivo pharmacodynamics, and pharmacokinetics. PAL-BE was fabricated via the injection-ultrasonication method, and its formulation was optimized using Box-Behnken design. The optimized PAL-BE appeared as a clear, transparent dispersion with pale blue opalescence and exhibited excellent stability at 4 °C. Fourier-transform infrared (FT-IR) spectroscopy verified the formation of hydrogen bonds between palonosetron (PAL) and excipients, with no chemical interactions detected. Subsequently, PAL-BE-G was prepared with 0.5% carbomer 940 as the gel matrix, which maintained favorable storage stability at 4 °C for 120 days. In vitro release assays showed a 94% cumulative release rate of PAL within 36 h, confirming the sustained-release property of the gel. In vitro transdermal permeation studies demonstrated that PAL-BE-G possessed superior skin penetration efficiency. Safety evaluations confirmed the excellent biocompatibility of PAL-BE-G with no significant skin irritation. In vivo pharmacodynamic assays revealed that PAL-BE-G exerted comparable antiemetic efficacy against chemotherapy-induced nausea and vomiting (CINV) to commercial PAL injection. Pharmacokinetic studies indicated that the absolute bioavailability of PAL-BE-G was 18.74 ± 3.26%, with sustained drug release in vivo. In conclusion, the successfully developed PAL-BE-G integrates high transdermal permeability, ideal sustained-release behavior, and favorable safety profiles. It provides a novel therapeutic alternative for CINV patients, especially those unable to tolerate oral administration, and offers experimental and theoretical support for the transdermal delivery of poorly soluble drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.